A detailed history of Benedetti & Gucer, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Benedetti & Gucer, Inc. holds 14,668 shares of BMY stock, worth $850,744. This represents 0.39% of its overall portfolio holdings.

Number of Shares
14,668
Previous 19,462 24.63%
Holding current value
$850,744
Previous $998,000 20.34%
% of portfolio
0.39%
Previous 0.53%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$47.98 - $54.4 $230,016 - $260,793
-4,794 Reduced 24.63%
14,668 $795,000
Q4 2023

Feb 12, 2024

SELL
$48.48 - $57.85 $146,409 - $174,707
-3,020 Reduced 13.43%
19,462 $998,000
Q3 2023

Nov 02, 2023

BUY
$57.89 - $64.73 $142,235 - $159,041
2,457 Added 12.27%
22,482 $1.3 Million
Q2 2023

Jul 20, 2023

BUY
$63.71 - $70.74 $286,695 - $318,330
4,500 Added 28.99%
20,025 $1.28 Million
Q1 2023

Apr 26, 2023

BUY
$65.71 - $74.53 $1.02 Million - $1.16 Million
15,525 New
15,525 $1.08 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Benedetti & Gucer, Inc. Portfolio

Follow Benedetti & Gucer, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benedetti & Gucer, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benedetti & Gucer, Inc. with notifications on news.